Stocky turns companies like CALEDONIA INVESTMENTS PLC ORD 0 into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Hold. Celldex Therapeutics shows balanced growth and value characteristics (57.5 and 58 scores), but a Vulnerability Index of 100—driven by thin financial buffers and clinical-stage risk—demands caution. Leadership alignment is moderate (59/100), and near-term cash runway, not revenue moat, is the binding constraint. Watch for clinical trial catalysts; current risk-reward does not justify accumulation.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for CALEDONIA INVESTMENTS PLC ORD 0:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 60/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates CALEDONIA INVESTMENTS PLC ORD 0 (CLDN.L) at 60/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Hold. Celldex Therapeutics shows balanced growth and value characteristics (57.5 and 58 scores), but a Vulnerability Index of 100—driven by thin financial buffers and clinical-stage risk—demands caution. Leadership alignment is moderate (59
CLDN.L's current Stocky Verdict is 60/100, placing it in the "Hold" band. This composite combines a 58/100 Compounder score, 59/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for CALEDONIA INVESTMENTS PLC ORD 0 yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
CALEDONIA INVESTMENTS PLC ORD 0 scores 59/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
CALEDONIA INVESTMENTS PLC ORD 0's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to CALEDONIA INVESTMENTS PLC ORD 0.
Sign up free and unlock the full analysis on CLDN.L — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for CLDN.L in the app.
